Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ: TEM) announced a collaboration with Median Technologies to integrate eyonis® LCS into the Tempus Pixel platform on February 12, 2026. eyonis® LCS is an AI-based SaMD for lung cancer screening that received FDA 510(k) clearance earlier this month.
The integration will enable CT nodule detection, non-invasive characterization and a proprietary nodule malignancy score inside Tempus Pixel (an FDA-cleared, CE-marked imaging solution), aiming to help clinical teams prioritize patients and expand screening impact.
Tempus (NASDAQ: TEM) will report fourth-quarter and full-year 2025 financial results on February 24, 2026. The company will hold an earnings conference call at 4:30 pm ET featuring Founder & CEO Eric Lefkofsky and CFO Jim Rogers.
A live audio webcast will be available on Tempus' investor relations events page; dial-in details and Conference ID 4652845 were provided for U.S. and toll-free access.
Ambry Genetics (NASDAQ: TEM) contributed clinical data to a Nature Communications study using MAVEs to evaluate PALB2 missense variants. Researchers assayed 84% of missense variants across 11 exons, testing 6,718 variants: 3,904 normal (58%), 2,422 intermediate (36%), 392 abnormal (6%).
Findings support improved variant interpretation, thousands of patient reclassifications, and build on prior MAVE results for BRCA2 and MUTYH that enabled high theoretical classification rates.
Ambry Genetics (NASDAQ: TEM) announced completion of its one-millionth DNA/RNA test, marking widespread adoption of paired DNA/RNA diagnostics for hereditary cancer and rare disease. +RNAinsight (commercial since 2019) and RNA-enabled ExomeReveal (added 2024) improved detection: analysis of >450,000 patients found 1 in 25 positive cases would have been missed without RNA and a 6% reduction in variants of uncertain significance. The company highlighted greater impact on variant classification in non-White patients, aiming to improve diagnostic equity and clinical clarity.
Tempus (NASDAQ: TEM) announced clinical validation showing its AI-driven Immune Profile Score (IPS) more accurately predicts benefit from immune checkpoint inhibitors (ICIs) than conventional biomarkers TMB, MSI/MSS, and PD-L1. Across four independent pan-cancer metastatic cohorts IPS showed superior prognostic utility (HR=0.45). IPS flagged 13% of microsatellite-stable colorectal patients with strong real-world overall survival on ICI (HR=0.2) and classified 17% of rare metastatic solid tumor patients as “IPS-High” with a large survival difference (HR=0.26). The IPS test is offered as an add-on to clinicians ordering Tempus xT (DNA) and xR (RNA) assays.
Tempus (NASDAQ: TEM) announced on January 21, 2026 the launch of Paige Predict, an AI-powered digital pathology suite that analyzes H&E whole slide images to predict the likely presence or absence of clinically actionable biomarkers.
Paige Predict evaluates 123 biomarkers and oncogenic pathways across 16 cancer types, and was built using a combined multimodal cohort of de-identified data from over 200,000 patients. Results are delivered automatically with clinical reports to help clinicians prioritize confirmatory NGS or IHC testing when tissue is limited.
Tempus (NASDAQ:TEM) and NYU Langone Health announced a multi-year strategic collaboration on January 12, 2026 to advance precision oncology through advanced molecular profiling and data science.
The partnership will support NYU Langone’s Center for Molecular Oncology at the Perlmutter Cancer Center and launch a prospective observational study titled “Serial Molecular Profiling and Monitoring of Human Cancer”, sequencing patients throughout their treatment to collect longitudinal genomic data. Subsequent studies will target assay validation, biomarker discovery, biological modeling, real-world data analysis, and development of AI-powered predictive algorithms to refine diagnostics and inform clinical practice.
Northwestern Medicine and Tempus (NASDAQ: TEM) announced a collaboration to expand genomic testing access for Northwestern Medicine cancer patients, effective January 12, 2026.
The initiative aims to offer next-generation sequencing broadly across cancer types, including earlier-stage diagnoses, and to provide clinicians with DNA/RNA profiling, solid tissue testing, liquid biopsy, and minimal residual disease (MRD) assays. The partners expect the data to support more tailored treatments and to facilitate design of clinical trials for personalized cancer therapies.
Tempus (NASDAQ: TEM) reported a record Total Contract Value (TCV) >$1.1 billion as of December 31, 2025 and preliminary, unaudited Data and applications revenue of approximately $316 million for full-year 2025, about 31% year-over-year growth. Insights (data licensing) grew 38% and 2025 net revenue retention was approximately 126%. Tempus signed data agreements with more than 70 customers, including several large pharma companies. The results are preliminary and unaudited; Tempus expects to report complete fourth-quarter and full-year 2025 audited results on its February 2026 earnings call and notes final figures may differ materially from these estimates.
Tempus (NASDAQ: TEM) reported preliminary, unaudited results for Q4 and full-year 2025 showing strong growth. Full-year 2025 revenue was approximately $1.27 billion (+~83% YoY) with ~30% organic growth (excluding Ambry). Diagnostics revenue was ~$955 million (+~111% YoY) and Data & Applications revenue was ~$316 million (+~31% YoY). Q4 2025 revenue was ~$367 million (+~83% YoY) with Q4 Data & Applications at ~$100 million. Results are preliminary, unaudited, and subject to change; full results expected on the February 2026 earnings call.